Translate Bio, Inc. (TBIO): Price and Financial Metrics
TBIO Price/Volume Stats
|Current price||$1.52||52-week high||$3.83|
|Prev. close||$1.60||52-week low||$1.08|
|Day high||$1.68||Avg. volume||150,283|
|50-day MA||$2.51||Dividend yield||N/A|
|200-day MA||$1.93||Market Cap||45.17M|
TBIO Stock Price Chart Interactive Chart >
Translate Bio, Inc. (TBIO) Company Bio
Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is based in Lexington, Massachusetts.
Most Popular Stories View All
TBIO Latest News Stream
|Loading, please wait...|
TBIO Latest Social Stream
View Full TBIO Social Stream
Latest TBIO News From Around the Web
Below are the latest news stories about TELESIS BIO INC that investors may wish to consider to help them evaluate TBIO as an investment opportunity.
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit
New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology WorkstationSAN DIEGO, May 22, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp® Select DNA Cloning kit. The BioXp® Select DNA Cloning kit enables on-demand and automated assembly of DNA
Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit
New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology WorkstationSAN DIEGO, May 18, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced the first commercial shipment of its BioXp® NGS Library Prep kit for Plasmid Sequencing. This NGS Library Prep kit enables on-demand and automated library preparation of p
Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)
Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics ApplicationsSAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced they will be showcasing their benchtop automation solutions for DNA and mRNA synthesis at Protein Engineering Summit (PEGS Boston 2023) which begins today in Boston, Massachusetts. Daniel Gibson, Ph.D., CTO and Co-founder of Telesis Bio and th
Telesis Bio First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag
Telesis Bio ( NASDAQ:TBIO ) First Quarter 2023 Results Key Financial Results Revenue: US$6.32m (up 12% from 1Q 2022...
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TBIO Price Returns
Continue Researching TBIOWant to do more research on Translate Bio Inc's stock and its price? Try the links below:
Translate Bio Inc (TBIO) Stock Price | Nasdaq
Translate Bio Inc (TBIO) Stock Quote, History and News - Yahoo Finance
Translate Bio Inc (TBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...